Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration
<b>Background:</b> Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways to improve the immunogenicity of vaccines. <b>Methods:</b> In the immunogenicity study, 50 BALB/c mice were r...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/5/442 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256205335756800 |
|---|---|
| author | Haimei Zhao Zhen Zhang Yong Xue Nan Wang Yinping Liu Xihui Ma Lan Wang Xiaoou Wang Danyang Zhang Junxian Zhang Xueqiong Wu Yan Liang |
| author_facet | Haimei Zhao Zhen Zhang Yong Xue Nan Wang Yinping Liu Xihui Ma Lan Wang Xiaoou Wang Danyang Zhang Junxian Zhang Xueqiong Wu Yan Liang |
| author_sort | Haimei Zhao |
| collection | DOAJ |
| description | <b>Background:</b> Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways to improve the immunogenicity of vaccines. <b>Methods:</b> In the immunogenicity study, 50 BALB/c mice were randomly divided into the following: (1) phosphate buffered saline (PBS)+intramuscular injection combined with electroporation (EP) group (100 μL), (2) pVAX1+EP group (50 μg/100 μL), (3) <i>ag85ab</i>+EP group (50 μg/100 μL), (4) pVAX1+pulmonary delivery (PD) group (50 μg/50 μL), and (5) <i>ag85ab</i>+PD group (50 μg/50 μL). Immunization was given once every 2 weeks for a total of three times. The number of IFN-γ-secreting lung and spleen lymphocytes was determined by enzyme-linked immunospot assay (ELISPOT). The levels of Th1, Th2, and Th17 cytokines in the culture supernatants of lung and spleen lymphocytes were detected with the Luminex method. The proportion of FoxP3 regulatory T cells in splenocytes was determined by flow cytometry. The levels of IgG-, IgG1-, and IgG2a-specific antibodies in plasma and IgA antibody in bronchoalveolar lavage fluid (BALF) were determined by enzyme-linked immunosorbent assay (ELISA). <b>Results:</b> The PD and EP routes of <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>) <i>ag85ab</i> DNA vaccine can effectively induce the responses of IFN-γ-secreting lung and spleen lymphocytes, and induce dominant Th1 and Th17 cell immune responses. The PD route can induce earlier, greater numbers and stronger responses of pulmonary effector T cells, with higher levels of the specific antibody IgA detected in BALF. High levels of the specific antibodies IgG, IgG1, and IgG2α were detected in the plasma of mice immunized by the EP route. <b>Conclusions:</b> The PD route of DNA vaccines can more effectively stimulate the body to produce strong cellular and mucosal immunity than the EP route, especially local cellular immunity in the lungs, which can provide early protection for the lungs. It can significantly improve the immunogenicity of the <i>ag85ab</i> DNA vaccine, suggesting a feasible and effective approach to DNA immunization. |
| format | Article |
| id | doaj-art-3fcd3fef37174ebc9b50acd0d1f2248e |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-3fcd3fef37174ebc9b50acd0d1f2248e2025-08-20T01:56:42ZengMDPI AGVaccines2076-393X2025-04-0113544210.3390/vaccines13050442Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary AdministrationHaimei Zhao0Zhen Zhang1Yong Xue2Nan Wang3Yinping Liu4Xihui Ma5Lan Wang6Xiaoou Wang7Danyang Zhang8Junxian Zhang9Xueqiong Wu10Yan Liang11Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaGraduate School, Hebei North University, Zhangjiakou 075000, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, ChinaBeijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 100091 Beijing, China<b>Background:</b> Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways to improve the immunogenicity of vaccines. <b>Methods:</b> In the immunogenicity study, 50 BALB/c mice were randomly divided into the following: (1) phosphate buffered saline (PBS)+intramuscular injection combined with electroporation (EP) group (100 μL), (2) pVAX1+EP group (50 μg/100 μL), (3) <i>ag85ab</i>+EP group (50 μg/100 μL), (4) pVAX1+pulmonary delivery (PD) group (50 μg/50 μL), and (5) <i>ag85ab</i>+PD group (50 μg/50 μL). Immunization was given once every 2 weeks for a total of three times. The number of IFN-γ-secreting lung and spleen lymphocytes was determined by enzyme-linked immunospot assay (ELISPOT). The levels of Th1, Th2, and Th17 cytokines in the culture supernatants of lung and spleen lymphocytes were detected with the Luminex method. The proportion of FoxP3 regulatory T cells in splenocytes was determined by flow cytometry. The levels of IgG-, IgG1-, and IgG2a-specific antibodies in plasma and IgA antibody in bronchoalveolar lavage fluid (BALF) were determined by enzyme-linked immunosorbent assay (ELISA). <b>Results:</b> The PD and EP routes of <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>) <i>ag85ab</i> DNA vaccine can effectively induce the responses of IFN-γ-secreting lung and spleen lymphocytes, and induce dominant Th1 and Th17 cell immune responses. The PD route can induce earlier, greater numbers and stronger responses of pulmonary effector T cells, with higher levels of the specific antibody IgA detected in BALF. High levels of the specific antibodies IgG, IgG1, and IgG2α were detected in the plasma of mice immunized by the EP route. <b>Conclusions:</b> The PD route of DNA vaccines can more effectively stimulate the body to produce strong cellular and mucosal immunity than the EP route, especially local cellular immunity in the lungs, which can provide early protection for the lungs. It can significantly improve the immunogenicity of the <i>ag85ab</i> DNA vaccine, suggesting a feasible and effective approach to DNA immunization.https://www.mdpi.com/2076-393X/13/5/442<i>Mycobacterium tuberculosis</i>DNA vaccinepulmonary deliveryelectroporationimmunogenicity |
| spellingShingle | Haimei Zhao Zhen Zhang Yong Xue Nan Wang Yinping Liu Xihui Ma Lan Wang Xiaoou Wang Danyang Zhang Junxian Zhang Xueqiong Wu Yan Liang Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration Vaccines <i>Mycobacterium tuberculosis</i> DNA vaccine pulmonary delivery electroporation immunogenicity |
| title | Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration |
| title_full | Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration |
| title_fullStr | Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration |
| title_full_unstemmed | Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration |
| title_short | Evaluation of Immunogenicity of <i>Mycobacterium tuberculosis ag85ab</i> DNA Vaccine Delivered by Pulmonary Administration |
| title_sort | evaluation of immunogenicity of i mycobacterium tuberculosis ag85ab i dna vaccine delivered by pulmonary administration |
| topic | <i>Mycobacterium tuberculosis</i> DNA vaccine pulmonary delivery electroporation immunogenicity |
| url | https://www.mdpi.com/2076-393X/13/5/442 |
| work_keys_str_mv | AT haimeizhao evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT zhenzhang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT yongxue evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT nanwang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT yinpingliu evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT xihuima evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT lanwang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT xiaoouwang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT danyangzhang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT junxianzhang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT xueqiongwu evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration AT yanliang evaluationofimmunogenicityofimycobacteriumtuberculosisag85abidnavaccinedeliveredbypulmonaryadministration |